NO20084053L - Inhibering av tumorvekst - Google Patents

Inhibering av tumorvekst

Info

Publication number
NO20084053L
NO20084053L NO20084053A NO20084053A NO20084053L NO 20084053 L NO20084053 L NO 20084053L NO 20084053 A NO20084053 A NO 20084053A NO 20084053 A NO20084053 A NO 20084053A NO 20084053 L NO20084053 L NO 20084053L
Authority
NO
Norway
Prior art keywords
tumor growth
inhibition
lytic
vaccination
establishment
Prior art date
Application number
NO20084053A
Other languages
English (en)
Norwegian (no)
Inventor
Oystein Rekdal
John Sigurd Svendsen
Baldur Sveinbjornsson
Gerd Berge
Live Tone Eliassen
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Publication of NO20084053L publication Critical patent/NO20084053L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20084053A 2006-03-21 2008-09-24 Inhibering av tumorvekst NO20084053L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0605685.7A GB0605685D0 (en) 2006-03-21 2006-03-21 Inhibition of tumour growth
PCT/GB2007/000993 WO2007107748A2 (en) 2006-03-21 2007-03-21 Inhibition of tumour growth

Publications (1)

Publication Number Publication Date
NO20084053L true NO20084053L (no) 2008-11-28

Family

ID=36383910

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084053A NO20084053L (no) 2006-03-21 2008-09-24 Inhibering av tumorvekst

Country Status (8)

Country Link
EP (1) EP2010204A2 (OSRAM)
JP (1) JP2009530359A (OSRAM)
CN (1) CN101466391A (OSRAM)
AU (1) AU2007228574B2 (OSRAM)
CA (1) CA2646589C (OSRAM)
GB (1) GB0605685D0 (OSRAM)
NO (1) NO20084053L (OSRAM)
WO (1) WO2007107748A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821616D0 (en) * 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
GB201401877D0 (en) * 2014-02-04 2014-03-19 Univ Tromsoe Peptides
JP6813258B2 (ja) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス 化学療法の組み合わせ
JP6767096B2 (ja) 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
CA2976377A1 (en) * 2015-02-12 2016-08-18 The Johns Hopkins University Inhibition of yap for breaking tumor immune tolerance
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods
EP4637800A1 (en) 2022-12-20 2025-10-29 Lytix Biopharma AS Compositions comprising an oncolytic peptide and chitosan
WO2024133580A1 (en) 2022-12-20 2024-06-27 Lytix Biopharma As Medical products containing an aqueous formulation of a peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861478A (en) * 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
DE3854476T2 (de) * 1987-07-06 1996-04-04 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
US5773413A (en) * 1993-06-04 1998-06-30 Demeter Biotechnologies, Ltd. Method of combating mammalian neoplasias, and lytic peptides therefor
IL113244A0 (en) * 1994-04-08 1995-07-31 Demeter Biotech Ltd Method of combating mammalian neoplasia and lytic peptides therefor
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides

Also Published As

Publication number Publication date
WO2007107748A3 (en) 2007-12-06
GB0605685D0 (en) 2006-05-03
JP2009530359A (ja) 2009-08-27
AU2007228574A1 (en) 2007-09-27
EP2010204A2 (en) 2009-01-07
AU2007228574B2 (en) 2013-06-20
WO2007107748A2 (en) 2007-09-27
CA2646589C (en) 2016-05-03
CA2646589A1 (en) 2007-09-27
CN101466391A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
NO20084053L (no) Inhibering av tumorvekst
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
EP4306538A3 (en) Peptide oligonucleotide conjugates
MX374396B (es) Rocio de fentanilo sublingual.
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2011035205A3 (en) Antibodies against candida, collections thereof and methods of use
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
GB201001602D0 (en) Oligopeptidic compounds and uses therof
PH12013500559A1 (en) Combination therapy for treating hcv infection
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
MX2009012922A (es) Vacunacion intradermica de un peptido del virus del papiloma humano.
GEP20115293B (en) Isolated extract of walnuts, process for its obtaining and its use
EP2166845A4 (en) ALPHA CONNEXIN C TERMINAL (ACT) PEPTIDES FOR THE TREATMENT OF AGE-RELATED MACULAR AGENCY
NZ594347A (en) Antibodies against human tweak and uses thereof
MY209484A (en) Cpg amphiphiles and uses thereof
NO20054371L (no) Somatostatin-dopamin kimaere analoger
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
GB201018125D0 (en) Peptide
WO2007138382A3 (en) Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
MX380927B (es) Promotor de absorcion gi superior amortiguado.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application